SATB2 anticorps (AA 150-350)

N° du produit ABIN7870951

Cet anticorps anti-SATB2 Monoclonal Souris (Clone SATB2-7488) (ABIN7870951) détecte spécifiquement SATB2 dans IHC (p). L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour SATB2 anticorps (AA 150-350) (ABIN7870951)

Antigène: SATB2 (SATB Homeobox 2 (SATB2))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp SATB2 est non-conjugé

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: SATB2-7488

Détail du produit anti-SATB2 anticorps

Épitope: AA 150-350

Fonction: SATB2 Antibody

Purification: Protein A/G affinity

Immunogène: A recombinant partial protein sequence (within amino acids 150-350) from the human protein was used as the immunogen for the SATB2 antibody.

Isotype: IgG1, kappa

Information d'application

Indications d'application: Optimal dilution of the SATB2 antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Aliquot the SATB2 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Détails sur SATB2

Antigène: SATB2 (SATB Homeobox 2 (SATB2))

Autre désignation: SATB2

Sujet: SATB2 is a DNA binding protein that specifically binds nuclear matrix attachment regions. It is involved in transcription regulation and chromatin remodeling. SATB2 expression in colorectal carcinomas (CRC) is correlated with good prognosis and in laryngeal squamous cell carcinoma it functions as a tumor suppressor wherein loss of expression is positively correlated with high tumor grade and recurrence. Moreover, SATB2, in combination with CK20, could identify almost all CRC s. Upper gastrointestinal (GI) carcinomas and pancreatic ductal carcinomas are usually negative for SATB2, and ovarian carcinomas, lung adenocarcinomas, and adenocarcinomas from other origin are rarely positive for SATB2. Additionally, SATB2 antibody can identify neuroendocrine neoplasms of colon and rectum because SATB2 is usually negative in neuroendocrine neoplasms of the GI tract, pancreas, and lung. More recently, it has been reported that SATB2 is a sensitive marker for tumors with osteoblastic differentiation.

UniProt: Q9UPW6